Skip to main content
Erschienen in: Diabetology International 2/2022

31.01.2022 | Report of the Committee

New classification and diagnostic criteria for insulin resistance syndrome

verfasst von: Wataru Ogawa, Eiichi Araki, Yasushi Ishigaki, Yushi Hirota, Hiroshi Maegawa, Toshimasa Yamauchi, Tohru Yorifuji, Hideki Katagiri

Erschienen in: Diabetology International | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

This report of a working group established by the Japan Diabetes Society proposes a new classification and diagnostic criteria for insulin resistance syndrome. Insulin resistance syndrome is defined as a condition characterized by severe attenuation of insulin action due to functional impairment of the insulin receptor or its downstream signaling molecules. This syndrome is classified into two types: genetic insulin resistance syndrome, caused by gene abnormalities, and type B insulin resistance syndrome, caused by autoantibodies to the insulin receptor. Genetic insulin resistance syndrome includes type A insulin resistance as well as Donohue and Rabson-Mendenhall syndromes, all of which are caused by abnormalities of the insulin receptor gene; conditions such as SHORT syndrome caused by abnormalities of PIK3R1, which encodes a regulatory subunit of phosphatidylinositol 3-kinase; conditions caused by abnormalities of AKT2, TBC1D4, or PRKCE; and conditions in which a causative gene has not yet been identified. Type B insulin resistance syndrome is characterized by severe impairment of insulin action due to the presence of insulin receptor autoantibodies. Cases in which hypoglycemia alone is induced by autoantibodies that stimulate insulin receptor were not included in Type B insulin resistance syndrome.
Literatur
1.
Zurück zum Zitat Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, Roth J. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976;294:739–45.CrossRef Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, Roth J. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976;294:739–45.CrossRef
2.
Zurück zum Zitat Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore). 2004;83:209–22.CrossRef Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore). 2004;83:209–22.CrossRef
3.
Zurück zum Zitat Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore). 2002;81:87–100.CrossRef Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore). 2002;81:87–100.CrossRef
4.
Zurück zum Zitat Araki S, Kasuga M. Insulin receptor abnormalities [type A and type B]. Nihon Rinsho. 1998;56(Suppl 3):579–83 (In Japanese).PubMed Araki S, Kasuga M. Insulin receptor abnormalities [type A and type B]. Nihon Rinsho. 1998;56(Suppl 3):579–83 (In Japanese).PubMed
5.
Zurück zum Zitat George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini CL, Dunger DB, Barford D, Umpleby AM, Wareham NJ, Davies HA, Schafer AJ, Stoffel M, O’Rahilly S, Barroso I. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science. 2004;304:1325–8.CrossRef George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini CL, Dunger DB, Barford D, Umpleby AM, Wareham NJ, Davies HA, Schafer AJ, Stoffel M, O’Rahilly S, Barroso I. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science. 2004;304:1325–8.CrossRef
6.
Zurück zum Zitat Dash S, Sano H, Rochford JJ, Semple RK, Yeo G, Hyden CS, Soos MA, Clark J, Rodin A, Langenberg C, Druet C, Fawcett KA, Tung YC, Wareham NJ, Barroso I, Lienhard GE, O’Rahilly S, Savage DB. A truncation mutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemia. Proc Natl Acad Sci USA. 2009;106:9350–5.CrossRef Dash S, Sano H, Rochford JJ, Semple RK, Yeo G, Hyden CS, Soos MA, Clark J, Rodin A, Langenberg C, Druet C, Fawcett KA, Tung YC, Wareham NJ, Barroso I, Lienhard GE, O’Rahilly S, Savage DB. A truncation mutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemia. Proc Natl Acad Sci USA. 2009;106:9350–5.CrossRef
7.
Zurück zum Zitat Thauvin-Robinet C, Auclair M, Duplomb L, Caron-Debarle M, Avila M, St-Onge J, Le Merrer M, Le Luyer B, Héron D, Mathieu-Dramard M, Bitoun P, Petit JM, Odent S, Amiel J, Picot D, Carmignac V, Thevenon J, Callier P, Laville M, Reznik Y, Fagour C, Nunes ML, Capeau J, Lascols O, Huet F, Faivre L, Vigouroux C, Rivière JB. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. Am J Hum Genet. 2013;93:141–9.CrossRef Thauvin-Robinet C, Auclair M, Duplomb L, Caron-Debarle M, Avila M, St-Onge J, Le Merrer M, Le Luyer B, Héron D, Mathieu-Dramard M, Bitoun P, Petit JM, Odent S, Amiel J, Picot D, Carmignac V, Thevenon J, Callier P, Laville M, Reznik Y, Fagour C, Nunes ML, Capeau J, Lascols O, Huet F, Faivre L, Vigouroux C, Rivière JB. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. Am J Hum Genet. 2013;93:141–9.CrossRef
8.
Zurück zum Zitat Chudasama KK, Winnay J, Johansson S, Claudi T, König R, Haldorsen I, Johansson B, Woo JR, Aarskog D, Sagen JV, Kahn CR, Molven A, Njølstad PR. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am J Hum Genet. 2013;93:150–7.CrossRef Chudasama KK, Winnay J, Johansson S, Claudi T, König R, Haldorsen I, Johansson B, Woo JR, Aarskog D, Sagen JV, Kahn CR, Molven A, Njølstad PR. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am J Hum Genet. 2013;93:150–7.CrossRef
9.
Zurück zum Zitat Dyment DA, Smith AC, Alcantara D, Schwartzentruber JA, Basel-Vanagaite L, Curry CJ, Temple IK, Reardon W, Mansour S, Haq MR, Gilbert R, Lehmann OJ, Vanstone MR, Beaulieu CL, FORGE Canada Consortium, Majewski J, Bulman DE, O’Driscoll M, Boycott KM, Innes AM. Mutations in PIK3R1 cause SHORT syndrome. Am J Hum Genet. 2013;93:158–66.CrossRef Dyment DA, Smith AC, Alcantara D, Schwartzentruber JA, Basel-Vanagaite L, Curry CJ, Temple IK, Reardon W, Mansour S, Haq MR, Gilbert R, Lehmann OJ, Vanstone MR, Beaulieu CL, FORGE Canada Consortium, Majewski J, Bulman DE, O’Driscoll M, Boycott KM, Innes AM. Mutations in PIK3R1 cause SHORT syndrome. Am J Hum Genet. 2013;93:158–66.CrossRef
10.
Zurück zum Zitat Toshihiro M, Katagiri H, Kataoka K, Fukushima A, Segawa T, Fujiwara T, Hikichi I, Takebe N, Satoh J. Recurrent hypoglycemia during pregnancies in a woman with multiple autoantibodies including anti-insulin receptor antibody and anti-platelet antibody, whose serum lowered murine blood glucose levels and phosphorylated insulin receptor of CHO-IR cells. Endocr J. 2011;58:1037–43.CrossRef Toshihiro M, Katagiri H, Kataoka K, Fukushima A, Segawa T, Fujiwara T, Hikichi I, Takebe N, Satoh J. Recurrent hypoglycemia during pregnancies in a woman with multiple autoantibodies including anti-insulin receptor antibody and anti-platelet antibody, whose serum lowered murine blood glucose levels and phosphorylated insulin receptor of CHO-IR cells. Endocr J. 2011;58:1037–43.CrossRef
11.
Zurück zum Zitat Takeuchi T, Ishigaki Y, Hirota Y, Hasegawa Y, Yorifuji T, Kadowaki H, Akamizu T, Ogawa W, Katagiri H. Clinical characteristics of insulin resistance syndromes: a nationwide survey in Japan. J Diabetes Investig. 2020;11:603–16.CrossRef Takeuchi T, Ishigaki Y, Hirota Y, Hasegawa Y, Yorifuji T, Kadowaki H, Akamizu T, Ogawa W, Katagiri H. Clinical characteristics of insulin resistance syndromes: a nationwide survey in Japan. J Diabetes Investig. 2020;11:603–16.CrossRef
12.
Zurück zum Zitat Semple RK, Savage DB, Cochran EK, Gorden P, O’Rahilly S. Genetic syndromes of severe insulin resistance. Endocr Rev. 2011;32:498–514.CrossRef Semple RK, Savage DB, Cochran EK, Gorden P, O’Rahilly S. Genetic syndromes of severe insulin resistance. Endocr Rev. 2011;32:498–514.CrossRef
13.
Zurück zum Zitat Longo N, Wang Y, Smith SA, Langley SD, DiMeglio LA, Giannella-Neto D. Genotype-phenotype correlation in inherited severe insulin resistance. Hum Mol Genet. 2002;11:1465–75.CrossRef Longo N, Wang Y, Smith SA, Langley SD, DiMeglio LA, Giannella-Neto D. Genotype-phenotype correlation in inherited severe insulin resistance. Hum Mol Genet. 2002;11:1465–75.CrossRef
14.
Zurück zum Zitat Kadowaki T, Bevins CL, Cama A, Ojamaa K, Marcus-Samuels B, Kadowaki H, Beitz L, McKeon C, Taylor SI. Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science. 1988;240:787–90.CrossRef Kadowaki T, Bevins CL, Cama A, Ojamaa K, Marcus-Samuels B, Kadowaki H, Beitz L, McKeon C, Taylor SI. Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science. 1988;240:787–90.CrossRef
15.
Zurück zum Zitat Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes. 1992;41:1473–90.CrossRef Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes. 1992;41:1473–90.CrossRef
16.
Zurück zum Zitat Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85–96.CrossRef Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85–96.CrossRef
17.
Zurück zum Zitat Schwingshandl J, Mache CJ, Rath K, Borkenstein MH. SHORT syndrome and insulin resistance. Am J Med Genet. 1993;47:907–9.CrossRef Schwingshandl J, Mache CJ, Rath K, Borkenstein MH. SHORT syndrome and insulin resistance. Am J Med Genet. 1993;47:907–9.CrossRef
18.
Zurück zum Zitat Avila M, Dyment DA, Sagen JV, St-Onge J, Moog U, Chung BHY, Mo S, Mansour S, Albanese A, Garcia S, Martin DO, Lopez AA, Claudi T, König R, White SM, Sawyer SL, Bernstein JA, Slattery L, Jobling RK, Yoon G, Curry CJ, Merrer ML, Luyer BL, Héron D, Mathieu-Dramard M, Bitoun P, Odent S, Amiel J, Kuentz P, Thevenon J, Laville M, Reznik Y, Fagour C, Nunes ML, Delesalle D, Manouvrier S, Lascols O, Huet F, Binquet C, Faivre L, Rivière JB, Vigouroux C, Njølstad PR, Innes AM, Thauvin-Robinet C. Clinical reappraisal of SHORT syndrome with PIK3R1 mutations: toward recommendation for molecular testing and management. Clin Genet. 2016;89:501–6.CrossRef Avila M, Dyment DA, Sagen JV, St-Onge J, Moog U, Chung BHY, Mo S, Mansour S, Albanese A, Garcia S, Martin DO, Lopez AA, Claudi T, König R, White SM, Sawyer SL, Bernstein JA, Slattery L, Jobling RK, Yoon G, Curry CJ, Merrer ML, Luyer BL, Héron D, Mathieu-Dramard M, Bitoun P, Odent S, Amiel J, Kuentz P, Thevenon J, Laville M, Reznik Y, Fagour C, Nunes ML, Delesalle D, Manouvrier S, Lascols O, Huet F, Binquet C, Faivre L, Rivière JB, Vigouroux C, Njølstad PR, Innes AM, Thauvin-Robinet C. Clinical reappraisal of SHORT syndrome with PIK3R1 mutations: toward recommendation for molecular testing and management. Clin Genet. 2016;89:501–6.CrossRef
19.
Zurück zum Zitat Alcantara D, Elmslie F, Tetreault M, Bareke E, Hartley T, Care4Rare Consortium, Majewski J, Boycott K, Innes AM, Dyment DA, O’Driscoll M. SHORT syndrome due to a novel de novo mutation in PRKCE (Protein Kinase Cɛ) impairing TORC2-dependent AKT activation. Hum Mol Genet. 2017;26:3713–21.CrossRef Alcantara D, Elmslie F, Tetreault M, Bareke E, Hartley T, Care4Rare Consortium, Majewski J, Boycott K, Innes AM, Dyment DA, O’Driscoll M. SHORT syndrome due to a novel de novo mutation in PRKCE (Protein Kinase Cɛ) impairing TORC2-dependent AKT activation. Hum Mol Genet. 2017;26:3713–21.CrossRef
20.
Zurück zum Zitat Bloise W, Wajchenberg BL, Moncada VY, Marcus-Samuels B, Taylor SI. Atypical antiinsulin receptor antibodies in a patient with type B insulin resistance and scleroderma. J Clin Endocrinol Metab. 1989;68:227–31.CrossRef Bloise W, Wajchenberg BL, Moncada VY, Marcus-Samuels B, Taylor SI. Atypical antiinsulin receptor antibodies in a patient with type B insulin resistance and scleroderma. J Clin Endocrinol Metab. 1989;68:227–31.CrossRef
21.
Zurück zum Zitat Imai J, Yamada T, Saito T, Ishigaki Y, Hinokio Y, Kotake H, Oka Y, Katagiri H. Eradication of insulin resistance. Lancet. 2009;374:264.CrossRef Imai J, Yamada T, Saito T, Ishigaki Y, Hinokio Y, Kotake H, Oka Y, Katagiri H. Eradication of insulin resistance. Lancet. 2009;374:264.CrossRef
22.
Zurück zum Zitat Saito-Hakoda A, Nishii A, Uchida T, Kikuchi A, Kanno J, Fujiwara I, Kure S. A follow-up during puberty in a Japanese girl with type A insulin resistance due to a novel mutation in INSR. Clin Pediatr Endocrinol. 2018;27:53–7.CrossRef Saito-Hakoda A, Nishii A, Uchida T, Kikuchi A, Kanno J, Fujiwara I, Kure S. A follow-up during puberty in a Japanese girl with type A insulin resistance due to a novel mutation in INSR. Clin Pediatr Endocrinol. 2018;27:53–7.CrossRef
23.
Zurück zum Zitat Harada M, Uchigata Y, Kataoka N, Miura J, Mochizuki H, Yanagisawa K, Sakura H, Iwamoto Y. A case of diabetes mellitus caused by a type A insulin receptor abnormality who has been treated with insulin-like growth actor 1 and oral glycemic agents for 19 years. J Jpn Diabetes Soc. 2010;53:626–30 (In Japanese). Harada M, Uchigata Y, Kataoka N, Miura J, Mochizuki H, Yanagisawa K, Sakura H, Iwamoto Y. A case of diabetes mellitus caused by a type A insulin receptor abnormality who has been treated with insulin-like growth actor 1 and oral glycemic agents for 19 years. J Jpn Diabetes Soc. 2010;53:626–30 (In Japanese).
24.
Zurück zum Zitat Donohue WL, Uchida I. Leprechaunism: a euphemism for a rare familial disorder. J Pediatr. 1954;45:505–19.CrossRef Donohue WL, Uchida I. Leprechaunism: a euphemism for a rare familial disorder. J Pediatr. 1954;45:505–19.CrossRef
25.
Zurück zum Zitat Kushi R, Hirota Y, Ogawa W. Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway. Diabetol Int. 2020;12:62–7.CrossRef Kushi R, Hirota Y, Ogawa W. Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway. Diabetol Int. 2020;12:62–7.CrossRef
26.
Zurück zum Zitat Petrovski S, Parrott RE, Roberts JL, Huang H, Yang J, Gorentla B, Mousallem T, Wang E, Armstrong M, McHale D, MacIver NJ, Goldstein DB, Zhong XP, Buckley RH. Dominant splice site mutations in PIK3R1 cause hyper IgM syndrome, lymphadenopathy and short stature. J Clin Immunol. 2016;36:462–71.CrossRef Petrovski S, Parrott RE, Roberts JL, Huang H, Yang J, Gorentla B, Mousallem T, Wang E, Armstrong M, McHale D, MacIver NJ, Goldstein DB, Zhong XP, Buckley RH. Dominant splice site mutations in PIK3R1 cause hyper IgM syndrome, lymphadenopathy and short stature. J Clin Immunol. 2016;36:462–71.CrossRef
27.
Zurück zum Zitat Ando A, Yatagai T, Rokkaku K, Nagasaka S, Ishikawa S, Ishibashi S. Obesity is a critical risk factor for worsening of glucose tolerance in a family with the mutant insulin receptor. Diabetes Care. 2002;25:1484–5.CrossRef Ando A, Yatagai T, Rokkaku K, Nagasaka S, Ishikawa S, Ishibashi S. Obesity is a critical risk factor for worsening of glucose tolerance in a family with the mutant insulin receptor. Diabetes Care. 2002;25:1484–5.CrossRef
28.
Zurück zum Zitat Højlund K, Hansen T, Lajer M, Henriksen JE, Levin K, Lindholm J, Pedersen O, Beck-Nielsen H. A novel syndrome of autosomal-dominant hyperinsulinaemic hypoglycaemia linked to a mutation in the human insulin receptor gene. Diabetes. 2004;53:1592–8.CrossRef Højlund K, Hansen T, Lajer M, Henriksen JE, Levin K, Lindholm J, Pedersen O, Beck-Nielsen H. A novel syndrome of autosomal-dominant hyperinsulinaemic hypoglycaemia linked to a mutation in the human insulin receptor gene. Diabetes. 2004;53:1592–8.CrossRef
29.
Zurück zum Zitat Hamaguchi T, Hirota Y, Takeuchi T, Nakagawa Y, Matsuoka A, Matsumoto M, Awano H, Iijima K, Cha PC, Satake W, Toda T, Ogawa W. Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitor. J Diabetes Investig. 2018;9:1224–7.CrossRef Hamaguchi T, Hirota Y, Takeuchi T, Nakagawa Y, Matsuoka A, Matsumoto M, Awano H, Iijima K, Cha PC, Satake W, Toda T, Ogawa W. Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitor. J Diabetes Investig. 2018;9:1224–7.CrossRef
30.
Zurück zum Zitat Nagashima S, Wakabayashi T, Saito N, Takahashi M, Okada K, Ebihara K, Ishibashi S. Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome. J Diabetes Investig. 2020;11:1363–5.CrossRef Nagashima S, Wakabayashi T, Saito N, Takahashi M, Okada K, Ebihara K, Ishibashi S. Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome. J Diabetes Investig. 2020;11:1363–5.CrossRef
31.
Zurück zum Zitat Nakae J, Kato M, Murashita M, Shinohara N, Tajima T, Fujieda K. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. J Clin Endocrinol Metab. 1998;83:542–9.CrossRef Nakae J, Kato M, Murashita M, Shinohara N, Tajima T, Fujieda K. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. J Clin Endocrinol Metab. 1998;83:542–9.CrossRef
Metadaten
Titel
New classification and diagnostic criteria for insulin resistance syndrome
verfasst von
Wataru Ogawa
Eiichi Araki
Yasushi Ishigaki
Yushi Hirota
Hiroshi Maegawa
Toshimasa Yamauchi
Tohru Yorifuji
Hideki Katagiri
Publikationsdatum
31.01.2022
Verlag
Springer Singapore
Erschienen in
Diabetology International / Ausgabe 2/2022
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-022-00570-5

Weitere Artikel der Ausgabe 2/2022

Diabetology International 2/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.